We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
ECP versus ruxolitinib in steroid-refractory acute GVHD – a retrospective study by the EBMT transplant complications working party.
- Authors
Penack, Olaf; Peczynski, Christophe; Boreland, William; Lemaitre, Jessica; Afanasyeva, Ksenia; Kornblit, Brian; Jurado, Manuel; Martinez, Carmen; Natale, Annalisa; Antonio Pérez-Simón, Jose; Brunello, Lucia; Avenoso, Daniele; Klein, Stefan; Ozkurt, Zubeyde Nur; Herrera, Concha; Wichert, Stina; Chiusolo, Patrizia; Gavriilaki, Eleni; Basak, Grzegorz W.; Schoemans, Hélène
- Abstract
Introduction: Extracorporal Photophoresis (ECP) is in clinical use for steroidrefractory and steroid-dependent acute GVHD (SR-aGVHD). Based on recent Phase-III study results, ruxolitinib has become the new standard of care for SRaGVHD. Our aim was to collect comparative data between ruxolitinib and ECP in SR-aGVHD in order to improve the evidence base for clinical decision making. Methods: We asked EBMT centers if they were willing to participate in this study by completing a data form (Med-C) with detailed information on GVHD grading, -therapy, -dosing, -response and complications for each included patient. Results: 31 centers responded positively (14%) and we included all patients receiving alloSCT between 1/2017-7/2019 and treated with ECP or ruxolitinib for SR-aGVHD grades II-IV from these centers. We identified 53 and 40 patients with grades II-IV SR-aGVHD who were treated with ECP and ruxolitinib, respectively. We performed multivariate analyses adjusted on grading and type of SR-aGVHD (steroid dependent vs. refractory). At day+90 after initiation of treatment for SR-aGVHD we found no statistically significant differences in overall response. The odds ratio in the ruxolitinib group to achieve overall response vs. the ECP group was 1.13 (95% CI = [0.41; 3.22], p = 0.81). In line, we detected no statistically significant differences in overall survival, progressionfree survival, non-relapse mortality and relapse incidence. Discussion: The clinical significance is limited by the retrospective study design and the current data can’t replace prospective studies on ECP in SR-aGVHD. However, the present results contribute to the accumulating evidence on ECP as an effective treatment option in SR-aGVHD.
- Subjects
RUXOLITINIB; RETROSPECTIVE studies; MULTIVARIATE analysis; STEM cell transplantation; ODDS ratio
- Publication
Frontiers in Immunology, 2023, p1
- ISSN
1664-3224
- Publication type
Article
- DOI
10.3389/fimmu.2023.1283034